Menu

FDA Approves Durvalumab Plus Enfortumab Vedotin for Perioperative Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Author: medicalhalo
Release time: 2026-11-16 03:05:46

  Muscle-invasive bladder cancer(MIBC)invades the detrusor muscle and usually corresponds to T2 or higher stage,carrying greater risks of local progression and metastasis than non-muscle-invasive disease.Radical cystectomy is central local therapy,and cisplatin-based neoadjuvant chemotherapy benefits selected patients.However,patients with impaired renal function,poor performance status,or refusal of cisplatin have long had limited perioperative options.

  On November 13,2026,the FDA approved durvalumab(Imfinzi)plus enfortumab vedotin-ejfv for adults with MIBC who are ineligible for or decline cisplatin-based chemotherapy.The approved model includes neoadjuvant combination therapy,radical cystectomy,and postoperative adjuvant durvalumab.

  Clinical Evidence and Efficacy

  The decision mainly rests on the phase 3 VOLGA trial(NCT04960709)in 695 patients ineligible for or declining cisplatin.The reported dual-drug perioperative arm used neoadjuvant durvalumab plus enfortumab vedotin,radical cystectomy,and adjuvant durvalumab versus surgery alone or standard adjuvant where approved.Versus the control surgery pathway,event-free survival(EFS)had HR about 0.51,a 49%relative reduction in event risk,with 24-month EFS about 64%versus 45%;overall survival(OS)had HR about 0.58,a 42%relative reduction in death risk,with 24-month OS about 78%versus 69%;locally assessed pathological complete response was about 45%versus 10%.These data support a cisplatin-sparing perioperative strategy to delay recurrence and improve long-term outcomes.

  Treatment Pathway

  Neoadjuvant:durvalumab plus enfortumab vedotin for several preoperative cycles to reduce tumor burden and increase pathological downstaging.

  Surgery:planned radical cystectomy with pelvic lymph node management.

  Adjuvant:continued durvalumab for defined postoperative cycles to address micrometastatic disease.

  Exact cycles and doses follow the local prescribing information;VOLGA used neoadjuvant durvalumab 1500mg with enfortumab vedotin 1.25mg/kg on day 1 and day 8,then adjuvant durvalumab maintenance.

  Safety and Monitoring

  Durvalumab is a PD-L1 checkpoint inhibitor;enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate.Common toxicities include rash,pruritus,fatigue,nausea,diarrhea,decreased appetite,alopecia,peripheral neuropathy,and musculoskeletal pain.Enfortumab vedotin requires active assessment for numbness,tingling,and sensory loss.Immune-related adverse events include pneumonitis,hepatitis,colitis,thyroid dysfunction,and other endocrine disturbances;persistent cough,dyspnea,jaundice,severe diarrhea,palpitations,or unexplained fatigue should prompt evaluation.In the VOLGA dual-drug arm,grade 3 or higher treatment-related adverse events were about 30%,and treatment-related cancellation of surgery was uncommon,but individualized benefit-risk assessment remains essential.

  Eligibility Boundaries

  The approval targets adults with MIBC who are cisplatin-ineligible or decline cisplatin.Cisplatin-eligible candidates should still be evaluated for standard cisplatin neoadjuvant therapy.Perioperative planning requires joint urology and oncology assessment of performance status,renal function,neurologic symptoms,autoimmune conditions,and surgical resectability.

  Corresponding Chinese Clinical Departments

  Urology,Medical Oncology,Urologic Oncology Multidisciplinary Clinic

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。

Durvalumab
描述
  【Indications】 Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody indicated for the treatment of adult patients with: [ 详情 ]
微信在线客服